Association Between Circulating Proprotein Convertase Subtilisin/Kexin Type 9 Concentrations and Cardiovascular Events in Cardiovascular Disease: A Systemic Review and Meta-Analysis

Background: A large amount of evidence suggests that proprotein convertase subtilisin/Kexin type 9 (PCSK9) inhibitors have clinical benefits in patients with cardiovascular disease (CVD). However, whether PCSK9 concentrations predict future cardiovascular (CV) events remains unclear. Methods: We con...

Descripción completa

Detalles Bibliográficos
Autores principales: Liu, Jiahui, Fan, Fangfang, Luo, Xingyu, Ji, Wenjun, Liu, Yaokun, Zhang, Yan, Zheng, Bo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Cardiovascular Medicine
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8650021/
https://www.ncbi.nlm.nih.gov/pubmed/34888364
http://dx.doi.org/10.3389/fcvm.2021.758956

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8650021/
https://www.ncbi.nlm.nih.gov/pubmed/34888364
http://dx.doi.org/10.3389/fcvm.2021.758956

Ejemplares similares